# Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt

> **NCT05813496** · PHASE4 · COMPLETED · sponsor: **Eva Pharma** · enrollment: 430 (actual)

## Conditions studied

- Polyneuropathy, Diabetic

## Interventions

- **DRUG:** Alpha-Lipoic Acid (ALA)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05813496
- **Lead sponsor:** Eva Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-26
- **Primary completion:** 2024-08-03
- **Final completion:** 2024-12-11
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2025-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05813496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05813496, "Phase IV Trial to Evaluate Efficacy of Alpha-Lipoic Acid in Treating Symptomatic Diabetic Polyneuropathy in Egypt". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05813496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*